HUE064701T2 - Valproinsavat tartalmazó, késleltetett felszabadulású gyógyszerkészítmények és azok felhasználása - Google Patents
Valproinsavat tartalmazó, késleltetett felszabadulású gyógyszerkészítmények és azok felhasználásaInfo
- Publication number
- HUE064701T2 HUE064701T2 HUE17723734A HUE17723734A HUE064701T2 HU E064701 T2 HUE064701 T2 HU E064701T2 HU E17723734 A HUE17723734 A HU E17723734A HU E17723734 A HUE17723734 A HU E17723734A HU E064701 T2 HUE064701 T2 HU E064701T2
- Authority
- HU
- Hungary
- Prior art keywords
- pharmaceutical formulations
- delayed release
- release pharmaceutical
- valproic acid
- valproic
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title 2
- 230000003111 delayed effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229960000604 valproic acid Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201606197 | 2016-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE064701T2 true HUE064701T2 (hu) | 2024-04-28 |
Family
ID=58709491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17723734A HUE064701T2 (hu) | 2016-04-08 | 2017-04-10 | Valproinsavat tartalmazó, késleltetett felszabadulású gyógyszerkészítmények és azok felhasználása |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11395808B2 (https=) |
| EP (1) | EP3439649B1 (https=) |
| JP (1) | JP6985368B2 (https=) |
| KR (1) | KR102438395B1 (https=) |
| CN (2) | CN109414423A (https=) |
| AU (1) | AU2017246697B2 (https=) |
| CA (1) | CA3018043A1 (https=) |
| ES (1) | ES2969021T3 (https=) |
| HU (1) | HUE064701T2 (https=) |
| IL (1) | IL262163B2 (https=) |
| MX (1) | MX395521B (https=) |
| PL (1) | PL3439649T3 (https=) |
| RU (1) | RU2760304C2 (https=) |
| WO (1) | WO2017175013A1 (https=) |
| ZA (1) | ZA201806766B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| CA3018043A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
| US20240285636A1 (en) * | 2021-06-14 | 2024-08-29 | Libbs Farmacêutica Ltda | Pharmaceutical composition and use of the pharmaceutical composition |
| CN113995742B (zh) * | 2021-10-22 | 2023-12-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 包含丙戊酸的美白组合物及其用途 |
| GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
| WO2026068561A1 (en) | 2024-09-24 | 2026-04-02 | Cereno Scientific Ab | Valproic acid for use in treating pulmonary arterial hypertension |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE68346T1 (de) | 1987-07-22 | 1991-11-15 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeurezubereitung und verfahren zu ihrer herstellung. |
| CN1228043C (zh) * | 1999-09-30 | 2005-11-23 | 爱德华·孟岱尔股份有限公司 | 用于高溶解度药物的缓释基质 |
| AT408718B (de) * | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
| AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
| US6610326B2 (en) * | 2001-02-16 | 2003-08-26 | Andrx Corporation | Divalproex sodium tablets |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| US20040224006A1 (en) | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
| ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
| US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| US20050276848A1 (en) * | 2004-06-15 | 2005-12-15 | Nilobon Podhipleux | Sustained release neutralized divalproex sodium |
| WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
| EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
| EP1937236A2 (en) | 2005-09-07 | 2008-07-02 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
| TWI393708B (zh) | 2005-09-08 | 2013-04-21 | Mei Pharma Inc | 異羥肟酸脂化合物，其用途及其之合成方法 |
| US20070082046A1 (en) * | 2005-10-11 | 2007-04-12 | Banner Pharmacaps, Inc. | Enteric valproic acid |
| DE602006003848D1 (de) * | 2006-01-11 | 2009-01-08 | Teva Pharma | Formulierung zur verzögerten Freisetzung von Valproinsäure und deren Derivate |
| WO2007084775A2 (en) | 2006-01-20 | 2007-07-26 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| US20090312311A1 (en) | 2006-04-06 | 2009-12-17 | Gary Michael Ksander | Combination of organic compounds |
| US20080069878A1 (en) | 2006-08-31 | 2008-03-20 | Gopi Venkatesh | Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs |
| GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
| WO2009009737A1 (en) * | 2007-07-12 | 2009-01-15 | Neurosci, Inc. | Sustained release formulation of active pharmaceuticals in a lipid based sustained release |
| US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
| GB201003766D0 (en) | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
| WO2011113013A2 (en) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Methods and compositions for treating viral or virally-induced conditions |
| CN101947209B (zh) * | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
| DK2683371T3 (da) * | 2011-03-09 | 2021-01-18 | Cereno Scient Ab | Forbindelser og fremgangsmåder til forbedring af forringet endogen fibrinolyse ved anvendelse af histondeacetylasehæmmere |
| JP6330118B2 (ja) | 2011-09-13 | 2018-05-30 | ファーマサイクリックス エルエルシー | ベンダムスチンと組み合わせたヒストンデアセチラーゼ阻害剤の製剤とその使用 |
| CN104248627A (zh) * | 2013-06-25 | 2014-12-31 | 北大方正集团有限公司 | 丙戊酸半钠泡腾干混悬剂及其制备方法 |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| CA3018043A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof |
| WO2017175010A1 (en) | 2016-04-08 | 2017-10-12 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
-
2017
- 2017-04-10 CA CA3018043A patent/CA3018043A1/en active Pending
- 2017-04-10 CN CN201780025746.XA patent/CN109414423A/zh active Pending
- 2017-04-10 KR KR1020187031904A patent/KR102438395B1/ko active Active
- 2017-04-10 US US16/090,664 patent/US11395808B2/en active Active
- 2017-04-10 MX MX2018012224A patent/MX395521B/es unknown
- 2017-04-10 PL PL17723734.4T patent/PL3439649T3/pl unknown
- 2017-04-10 RU RU2018137399A patent/RU2760304C2/ru active
- 2017-04-10 EP EP17723734.4A patent/EP3439649B1/en active Active
- 2017-04-10 AU AU2017246697A patent/AU2017246697B2/en active Active
- 2017-04-10 JP JP2019503794A patent/JP6985368B2/ja active Active
- 2017-04-10 WO PCT/GB2017/051002 patent/WO2017175013A1/en not_active Ceased
- 2017-04-10 CN CN202111575415.8A patent/CN114209667A/zh active Pending
- 2017-04-10 HU HUE17723734A patent/HUE064701T2/hu unknown
- 2017-04-10 ES ES17723734T patent/ES2969021T3/es active Active
-
2018
- 2018-10-07 IL IL262163A patent/IL262163B2/en unknown
- 2018-10-11 ZA ZA2018/06766A patent/ZA201806766B/en unknown
-
2022
- 2022-07-19 US US17/868,323 patent/US12023311B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017246697A1 (en) | 2018-10-04 |
| AU2017246697B2 (en) | 2022-06-02 |
| JP6985368B2 (ja) | 2021-12-22 |
| IL262163B1 (en) | 2023-03-01 |
| IL262163A (en) | 2018-11-29 |
| BR112018070626A2 (pt) | 2019-02-05 |
| EP3439649C0 (en) | 2023-11-15 |
| NZ746269A (en) | 2024-10-25 |
| RU2018137399A (ru) | 2020-05-12 |
| MX395521B (es) | 2025-03-25 |
| RU2018137399A3 (https=) | 2020-06-18 |
| US20190111011A1 (en) | 2019-04-18 |
| US20230120670A1 (en) | 2023-04-20 |
| RU2760304C2 (ru) | 2021-11-23 |
| EP3439649A1 (en) | 2019-02-13 |
| CN114209667A (zh) | 2022-03-22 |
| KR20180127480A (ko) | 2018-11-28 |
| IL262163B2 (en) | 2023-07-01 |
| EP3439649B1 (en) | 2023-11-15 |
| JP2019510834A (ja) | 2019-04-18 |
| ES2969021T3 (es) | 2024-05-16 |
| PL3439649T3 (pl) | 2024-03-18 |
| US12023311B2 (en) | 2024-07-02 |
| US11395808B2 (en) | 2022-07-26 |
| CN109414423A (zh) | 2019-03-01 |
| ZA201806766B (en) | 2024-03-27 |
| WO2017175013A1 (en) | 2017-10-12 |
| CA3018043A1 (en) | 2017-10-12 |
| MX2018012224A (es) | 2019-05-16 |
| KR102438395B1 (ko) | 2022-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304732A (en) | Orally administered amino acid compositions with a modified release | |
| IL256085B (en) | A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment | |
| ZA201806766B (en) | Delayed release pharmaceutical formulations comprising valproic acid, and uses thereof | |
| IL290114A (en) | Pharmaceutical preparations, their preparation and uses | |
| EP3102585A4 (en) | Boronic acid esters and pharmaceutical formulations thereof | |
| IL268678B (en) | Formulas of 1-amino-1-cyclopropane-carboxylic acid | |
| IL257143A (en) | Cetylated fatty acids, a system for their preparation and use | |
| IL262929B1 (en) | Preparations for treatment, methods of their preparation and their uses | |
| HUE056175T2 (hu) | Gyógyászati készítmények, elõállításuk és alkalmazásaik | |
| IL252397A0 (en) | Pharmaceutical preparations, their preparation and uses | |
| SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| LT3229843T (lt) | Farmacinė kompozicija, jos paruošimo būdas ir naudojimas | |
| IL280389A (en) | Bile acid receptor modulators conjugated to G.1 protein and methods of using them | |
| PL3253857T3 (pl) | Preparaty wodne, ich wytwarzanie i zastosowanie | |
| GB201511863D0 (en) | Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same |